Janux Therapeutics doses first patient in Phase 1 JANX013
Janux Therapeutics says the first patient has been dosed in its Phase 1 trial evaluating JANX013, a PSMA-targeted tumor-activated CD28 co-stimulatory bispecific.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.